Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
SNY
Sanofi
$47.62
Chart
$52.13 (-8.65%)
$54.5 (-12.62%)
$54.5 (-12.62%)
$49.66 (-4.11%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
SNY
Sanofi
Current Price
$47.62
Login to view Sanofi (SNY) recommendation from the last 90 days from financial news and social media.
Chart
$52.13 (-8.65%)
$54.5 (-12.62%)
$54.5 (-12.62%)
$49.66 (-4.11%)
SNY Latest Analysis
Sanofi successfully prices €1.5B bond issue.
Tue Jun 17, 2025
Sanofi Successfully Prices Offering Of EUR 1.5 Bln Of Notes Across 2 Tranches . (RTTNews) - French AI-powered biopharma company Sanofi SA (SNY) announced Tuesday it has successfully priced its offering of 1.5 billion of notes across 2 tranches.
Tue Jun 17, 2025
Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript.
Tue Jun 10, 2025
Beyfortus Output Tripled As Sanofi AstraZeneca Scale Up For RSV Season. French drugmaker ) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season which typically starts in November and .Sanofi in collaboration with its partner ) has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.Immunizations in early fall. The curr
Mon Jun 9, 2025
European stocks close lower on renewed trade worries. Sanofi buys United States rival.
Mon Jun 2, 2025
Sanofi to expand immunology offerings with Blueprint Medicines.
Mon Jun 2, 2025
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout. ) on Monday agreed to acquire ).The acquisition includes a rare immunology disease medicine Ayvakit/Ayvakyt (avapritinib) approved in the United States and the EU and a promising advanced and .Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM &. ISM) a rare immunology disease which is characterized by the accumulation and activation of aberrant mast cells in bone marrow skin the ga
Mon Jun 2, 2025
Blueprint Medicines stock soars on Sanofi acquisition deal.
Mon Jun 2, 2025
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline.
Mon Jun 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
